ATE367828T1 - Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel - Google Patents

Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel

Info

Publication number
ATE367828T1
ATE367828T1 AT99916414T AT99916414T ATE367828T1 AT E367828 T1 ATE367828 T1 AT E367828T1 AT 99916414 T AT99916414 T AT 99916414T AT 99916414 T AT99916414 T AT 99916414T AT E367828 T1 ATE367828 T1 AT E367828T1
Authority
AT
Austria
Prior art keywords
igf
injectable formulations
buffering agent
succinate
active agent
Prior art date
Application number
AT99916414T
Other languages
English (en)
Inventor
Bret Shirley
Maninder Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE367828T1 publication Critical patent/ATE367828T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99916414T 1998-04-03 1999-04-02 Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel ATE367828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8000898P 1998-04-03 1998-04-03

Publications (1)

Publication Number Publication Date
ATE367828T1 true ATE367828T1 (de) 2007-08-15

Family

ID=22154445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916414T ATE367828T1 (de) 1998-04-03 1999-04-02 Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel

Country Status (10)

Country Link
US (1) US20070249522A1 (de)
EP (1) EP1069912B1 (de)
JP (1) JP2002510653A (de)
AT (1) ATE367828T1 (de)
AU (1) AU3473999A (de)
DE (1) DE69936638T2 (de)
DK (1) DK1069912T3 (de)
ES (1) ES2288018T3 (de)
PT (1) PT1069912E (de)
WO (1) WO1999051272A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
EP1430113A2 (de) * 2001-09-18 2004-06-23 Stem Cell Therapeutics Inc. Wirkung von wachstumshormon und igf-1 auf neurale stammzellen und therapeutische anwendung
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
JP2006515882A (ja) 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
EP1928488A4 (de) 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp Regulierung der oligodendrozyten-vorläufer-zellproliferation mit prolactin
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020232274A1 (en) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
US11097023B1 (en) * 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0284249A1 (de) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Gefriergetrocknete Lymphokin-Zusammensetzung
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
DE68907066T2 (de) * 1988-01-29 1993-12-16 Koken Kk Verbesserte Formulierungen mit kontrollierter Abgabe.
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19825736C2 (de) * 1997-06-11 2003-09-18 Hyundai Electronics Ind Verfahren zum Bilden eines Kondensators einer Halbleitervorrichtung
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
US20070249522A1 (en) 2007-10-25
WO1999051272A1 (en) 1999-10-14
DK1069912T3 (da) 2007-11-12
AU3473999A (en) 1999-10-25
PT1069912E (pt) 2007-09-14
DE69936638D1 (de) 2007-09-06
EP1069912B1 (de) 2007-07-25
EP1069912A1 (de) 2001-01-24
DE69936638T2 (de) 2008-05-21
ES2288018T3 (es) 2007-12-16
JP2002510653A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
AU7328601A (en) Skin care compositions containing silicone elastomers
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
IL153297A0 (en) Compounds and compositions for delivering active agents
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
EA200000629A1 (ru) Стабилизированные растворы терипаратида
TW200626613A (en) Analogues of GLP-1
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
MY121684A (en) Non-aqueous protic peptide formulations
ATE367828T1 (de) Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
TNSN04249A1 (en) Acidic insulin preparations with improved stability
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
MY125556A (en) Aqueous formulations of peptide
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
EP0693924A4 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DK0876140T3 (da) Forbedrede kontrastmiddelopløsninger til intravasal anvendelse
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
NO20045507L (no) Injiserbare faste hyaluronsyrebaerere for levering av osteogene proteiner
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
GB9930768D0 (en) Composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1069912

Country of ref document: EP

REN Ceased due to non-payment of the annual fee